Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. - Ruan DY; Wu HX; Xu Y; Munster PN; Deng Y; Richardson G; Yan D; Lee MA; Lee KW; Pan H; Hager S; Li X; et al. (Signal transduction and targeted therapy, 2025)